Cardica Inc. (NASDAQ:DXTR) – Wedbush raised their FY2017 EPS estimates for Cardica in a report issued on Monday. Wedbush analyst Levy. T now anticipates that the firm will post earnings per share of ($1.01) for the year, up from their prior forecast of ($1.03). Wedbush has a “Outperform” rating and a $5.00 price objective on the stock. Wedbush also issued estimates for Cardica’s FY2018 earnings at ($0.91) EPS and FY2019 earnings at ($0.83) EPS.

Separately, Zacks Investment Research upgraded Cardica from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Friday, August 12th.

Earnings History and Estimates for Cardica (NASDAQ:DXTR)

Shares of Cardica (NASDAQ:DXTR) traded down 4.52% during trading on Thursday, hitting $1.48. The stock had a trading volume of 15,650 shares. The firm has a 50 day moving average price of $1.79 and a 200 day moving average price of $2.25. The firm’s market cap is $13.21 million. Cardica has a 12-month low of $1.10 and a 12-month high of $4.30.

Cardica (NASDAQ:DXTR) last announced its quarterly earnings data on Monday, November 7th. The company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.04.

Cardica Company Profile

Dextera Surgical Inc, formerly Cardica, Inc, is focused on the commercialization and development of microcutter product line intended for use by surgeons. The Company is engaged in commercializing and developing MicroCutter XCHANGE 30 based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

5 Day Chart for NASDAQ:DXTR

Receive News & Stock Ratings for Cardica Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardica Inc. and related stocks with our FREE daily email newsletter.